Welcome to our dedicated page for Revelation Biosciences SEC filings (Ticker: REVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Revelation Biosciences, Inc. (REVB) SEC filings page on Stock Titan provides organized access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI-generated summaries to help interpret complex documents. Revelation Biosciences is a clinical-stage life sciences company developing Gemini, a proprietary PHAD®-based TLR4 agonist targeting inflammation-driven conditions such as acute kidney injury, chronic kidney disease, post-surgical infection, and severe burn-related hyperinflammation.
Through this page, readers can review current and historical filings drawn from the SEC’s EDGAR system, including Form 8-K reports on material events and financing transactions, and definitive proxy statements on Schedule 14A for special meetings of stockholders. For example, recent 8-K filings describe warrant exercise inducement agreements, gross proceeds from warrant exercises, and the use of those proceeds for clinical development and corporate purposes. DEF 14A proxy statements outline proposals to authorize the issuance of common stock underlying new classes of warrants, explain Nasdaq share issuance limits, and provide details on virtual special meetings.
AI-powered tools on Stock Titan summarize lengthy filings, highlight key sections, and surface items such as capital raises, warrant terms, and changes affecting stockholder rights. Users can quickly identify disclosures related to warrant structures (including REVBW redeemable warrants), share authorization proposals, and other governance matters without reading every page manually.
In addition to event-driven reports, investors can use this filings hub to track how Revelation Biosciences describes its business focus on Gemini and inflammation modulation over time. As new quarterly, annual, and current reports are filed, they are added with real-time updates and concise AI explanations, helping users understand the regulatory context behind REVB’s clinical, financial, and capital markets activities.
Revelation Biosciences director Jess Roper reported receiving an equity award of 41,981 shares of common stock on January 8, 2026 at a price of $0.90 per share. After this grant, Roper directly beneficially owns 57,667 shares of the company’s common stock.
The award is described as a restricted stock unit grant under the 2021 Equity Incentive Plan, which vests quarterly over one year from the grant date. The filing also reflects an existing direct holding of 15,686 common shares, separate from the new restricted stock unit award.
Revelation Biosciences director Lakhmir S. Chawla reported an equity grant. On January 8, 2026, he acquired 41,981 shares of common stock at $0.90 per share, reported as an award under transaction code “A.” After this grant, he beneficially owned 57,667 shares of Revelation Biosciences common stock held directly.
The award represents a restricted stock unit grant under the 2021 Equity Incentive Plan, which vests quarterly over one year from the grant date. The filing reflects his status as a director of Revelation Biosciences, Inc. (ticker REVB) and indicates this was a Form 4 filed for a single reporting person.
Revelation Biosciences (REVB) filed a Form S-8 to register 4,647,222 additional shares of common stock for issuance under its 2021 Equity Incentive Plan. The filing incorporates prior S-8 registrations by reference under General Instruction E. This expands the pool of shares available for equity awards to employees, directors, and consultants.
Revelation Biosciences (REVB) called a Special Meeting on December 3, 2025 to seek stockholder approval to reserve and issue common shares upon exercise of Class I Warrants in amounts that may exceed Nasdaq’s 20% Exchange Cap under Rule 5635(d). A second proposal would allow adjournment if more votes are needed.
The request follows a September 2025 warrant inducement in which holders exercised 13,065,000 Class H Warrants into 4,355,000 shares at $2.20 per share, and received 13,065,000 Class I Warrants (exercisable for five years from stockholder approval at $2.20). The Company reported gross proceeds of approximately $9.6 million from this transaction.
Key mechanics: record date is October 29, 2025 with 5,924,137 shares outstanding; quorum is 1,974,713 shares. Warrant holders will vote their shares in the same proportion as disinterested stockholders. If Proposal 1 is not approved, the Company cannot issue or agree to issue common stock or equivalents and must hold meetings every 60 days; prior adjournments added about $50,000 in costs.
Revelation Biosciences, Inc. furnished an 8‑K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025.
The release is included as Exhibit 99.1 under Item 2.02 and will not be treated as “filed” or incorporated by reference unless expressly stated.
Revelation Biosciences (REVB) reported Q3 2025 results, highlighting higher liquidity alongside a continued net loss and a going concern warning. Cash and cash equivalents were $12.7 million as of September 30, 2025, up from $6.5 million at year-end, supported by financing activity.
For the quarter, the company recorded a net loss of $1.91 million on operating expenses of $1.94 million (R&D $0.92 million; G&A $1.02 million). For the nine months, the net loss was $6.40 million. Stockholders’ equity rose to $11.0 million. The share count increased following two reverse stock splits in 2025 and subsequent warrant-related issuances.
Management disclosed that current cash is not expected to sustain operations within one year after issuance of the financial statements, indicating substantial doubt about continuing as a going concern. Financing events included the May 2025 public offering with net proceeds of $3.4 million and a September 2025 Class H warrant inducement generating net proceeds of $8.7 million. As of November 4, 2025, 5,924,137 shares were outstanding.
Revelation Biosciences (REVB) director reported an equity grant. On 10/29/2025, the insider acquired 15,625 shares of common stock (Code A) at $1.28 per share under the 2021 Equity Incentive Plan. The award vests 100% on January 28, 2026. Following the grant, the reporting person beneficially owned 15,686 shares, held directly.
Revelation Biosciences (REVB) reported an insider equity grant. On 10/29/2025, CEO and Director James Rolke acquired 390,614 shares of common stock as a restricted stock grant under the 2021 Equity Incentive Plan.
The award vests quarterly over one year from the grant date. Following the transaction, Rolke beneficially owned 400,660 shares, held directly.
Revelation Biosciences (REVB) reported an insider equity award. A company director acquired 15,625 shares of Common Stock on 10/29/2025, reported at a $1.28 price per share, as a restricted stock grant under the 2021 Equity Incentive Plan.
The grant vests 100% on January 28, 2026. Following the transaction, the reporting person beneficially owned 15,688 shares, held directly.
Revelation Biosciences (REVB) reported an insider equity award for its Chief Financial Officer, Chester S. Zygmont III. On 10/29/2025, the CFO acquired 390,614 shares of common stock as a restricted stock grant under the 2021 Equity Incentive Plan at a stated price of $1.28 per share. The award vests quarterly over one year from the date of grant.
Following the reported transaction, the filing lists 395,645 shares of common stock indirectly held by The Zygmont Family Trust, and additional small indirect holdings of 5,026 shares by the trust and 5 shares by Czeslaw Capital Fund, LLC. The filing indicates the use of indirect ownership structures (trust and LLC) and confirms the CFO’s status as an officer.